Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash from Operations (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Cash from Operations for 8 consecutive years, with 17234000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 14.49% to 17234000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 97433000.0 through Dec 2025, down 63.62% year-over-year, with the annual reading at 97433000.0 for FY2025, 63.62% down from the prior year.
  • Cash from Operations for Q4 2025 was 17234000.0 at Whitehawk Therapeutics, down from 15378000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 10563000.0 in Q1 2021, with the low at 52957000.0 in Q2 2025.
  • Average Cash from Operations over 5 years is 14435450.0, with a median of 13740500.0 recorded in 2021.
  • The sharpest move saw Cash from Operations surged 368.11% in 2021, then tumbled 478.32% in 2025.
  • Over 5 years, Cash from Operations stood at 12428000.0 in 2021, then increased by 9.0% to 11310000.0 in 2022, then grew by 14.73% to 9644000.0 in 2023, then plummeted by 56.09% to 15053000.0 in 2024, then fell by 14.49% to 17234000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 17234000.0, 15378000.0, and 52957000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.